Richmond Becomes the UK's First CRO to be Based in 2 Acute NHS Teaching Hospitals

Posted:
3
May 2005

We are delighted to announce that we have opened a new facility at Mayday University Hospital to complement our units and offices in St George’s Hospital and St George’s University of London. This ground breaking move means Richmond Pharmacology is the UK’s first CROwith a dedicated Phase I and clinical trials unit to be based in 2 acute NHS Teaching Hospitals.Richmond’s pioneering new set-up enables clients to take advantage of on-site therapeutic consultancy with the optional control benefit of in-patient facilities.Dr Jörg Täubel, Managing Director, commented: “We have developed this platform to embrace the new Phase I patient studies. By basing our units and offices in acute university surroundings, we have developed our Integrated Trials Centre to operate as an SMO for Patient Studies. At the core of our offering is the ‘one centre’ solution – consultants, in-patient facilities and patient panels are all managed and delivered from within the same premises. This enables our clients to benefit from a focused, swift and efficient method of delivering Early Phase studies.”Dr Ulrike Lorch, Medical Director, added: “We are delighted and very excited by the opportunities this move offers our clients. Our new 60 bed unit in Mayday Hospital complements our facilities at St George’s Hospital perfectly. Our Phase I studies are conducted within the safety of acute flagship NHS surroundings, and it’s very pleasing to have consultants in numerous specialities just a door away.”“Our units also provide the in-patient control elements which gives our clients the flexibility to conduct Phase I patient studies, with all the benefits of acute NHS Trust facilities. Of course, our clients can still opt for the more traditionally defined Phase I and II studies; but we now offer far greater choice.” concluded Dr Täubel.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more